CN105362303A - Composition for treating inflammatory bowel disease - Google Patents
Composition for treating inflammatory bowel disease Download PDFInfo
- Publication number
- CN105362303A CN105362303A CN201510937003.2A CN201510937003A CN105362303A CN 105362303 A CN105362303 A CN 105362303A CN 201510937003 A CN201510937003 A CN 201510937003A CN 105362303 A CN105362303 A CN 105362303A
- Authority
- CN
- China
- Prior art keywords
- intestinal
- vitamin
- composition
- inflammatory bowel
- human body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a composition for treating an inflammatory bowel disease and belongs to the field of medicine. The composition is based on the principle that intestinal canal epithelium goblet cells are reinforced, a normal intestinal canal surface mucous layer barrier is constructed, antigens are prevented from getting close to, making contact with, adhering to and entering the intestinal wall, and therefore abnormal immune response and an inflammation are blocked. Lucid ganoderma has the function of enhancing human body blood supply and oxygen supply; vitamin C, vitamin E, vitamin A and beta-carotene have the effects of restraining oxygen free radial activity, clearing away oxygen free radicals and protecting human body cells. The composition provides nutrition, oxygen and raw materials for goblet cell generating, updating and repairing and the intestinal canal surface mucous layer barrier formed by mucoprotein secreted by the goblet cells. The composition has a remarkable effect on construction of the normal human body intestinal canal surface mucous layer barrier, stopping the inflammation and repairing intestinal tissue, and is an effective formula for treating the inflammatory bowel disease.
Description
Technical field
The present invention relates to the treatment Chinese crude drug of inflammatory bowel and the combination formula of vitamin, belong to medicine field.
Background technology
Inflammatory bowel (inflammatoryboweldisease, IBD) is the disease that a kind of pathogenic factor and pathogenesis are not yet completely clear and definite.Because pathogenic factor and pathogenesis are illustrated not yet completely, old friends can not fundamentally stop or delay the progress of this disease course.
Medical Immunology is thought, immune system occurs abnormal to antigen recognition and tolerance, namely normally perches the improper identification of microorganism to intestinal and produces immunne response, cause this disease.Histology and Embryology is then thought, intestinal permeability is too high, causes a large amount of Intestinal Antigens to enter intestinal tissue, has caused the permanent responsing reaction of immune system and has caused this disease.
At present the treatment of inflammatory bowel is taken as the leading factor with Medical Immunology, primary treatment measure be intervene, Immunosuppression response and inflammation to the damage of intestinal, as used glucocorticoid, aminosalicyclic acid supplement, monoclonal antibody, immunosuppressant etc.Above-mentioned remedy measures effect is undesirable and side effect large, so, to the research of the inflammatory bowel cause of disease, find pathogenic factor, take corresponding remedy measures to be the instant task of medical circle.
Summary of the invention
The present invention is based on modern medicine, the basis probing into inflammatory bowel pathogenic factor proposes the remedy measures of oneself, namely intestinal tissue and epithelial goblet cell is reinforced, build normal intestinal tract surface slime layer barrier, stop Intestinal Antigens close, contact, adhere to and enter intestinal tissue, thus block the generation of abnormal immune response, stop the intestinal tissue of inflammation, repairing damage simultaneously.
If carrying out intervention to the immunne response occurred and inflammation is try to stop water from boiling by skimming it off and pouring it back, and prescription therapeutic measure so of the present invention is removing burning wood away under the boiler.
First the gut muco-membranous barrier of human body is intestinal tract surface slime layer barrier, and intestinal tract surface slime layer barrier is the first line of defence of gut muco-membranous barrier.What intestinal tract surface slime layer was secreted by gut epithelium goblet cell mucoproteinly forms.The function of normal intestinal tract surface slime layer be stop the microorganism in intestinal comprise pathogenic microorganism, normally perch microorganism close with food source property antigen, contact, adhere to and enter gut epithelium and intestinal walls, and " attempt " is passed through to microorganism particularly pathogenic microorganism performance adhesion and the effect of parcel of surperficial slime layer, avoid the generation of abnormal immune response and inflammation.
Intestinal slime layer barrier has certain fluctuation, causes a small amount of microbes antigen or food source property antigen to pass through intestinal tract surface slime layer, close, contact, adhere to and enter gut epithelium.These antigens passing through intestinal tract surface slime layer first identify by the pattern recognition receptors of inherent immunity system (PRRs) and cause innate immune response to remove antigen.
When innate immune response can not remove antigen, antigen can by antigen presenting cell (APC) as macrophage (Μ φ), dendritic cell (DC) etc. be absorbed, are offered and cause adaptive immune response.Adaptive immune response enters immune system in the Process of Antigen of intestinal tissue in removing can discharge a large amount of secretory immunoglobulin As (secretorylffA, slgA) to enteric cavity.Can be combined with antigen specifically after slgA releases people's enteric cavity, suppress or kill bacteria, neutralization virus, prevent antigen close, contact, adhere to and enter enteric epithelium, thus reach immunologic balance.
The imbalance of intestinal tract surface slime layer barrier cause Intestinal Antigens in a large number close, contact, adhere to and enter intestinal wall, immune system cannot remove antigen in time, thus immunologic balance is broken, exception throw immunne response and inflammation, damage intestinal tissue, this is the pathogenic factor of inflammatory bowel.
The reason of intestinal tract surface slime layer barrier imbalance may be the performance of goblet cell abnormal condition, comprises the defect of goblet cell, deficiency and renewal, dysfunction; Also may be that goblet cell secretes mucoprotein obstacle.The main cause that goblet cell abnormal condition and goblet cell secrete mucoprotein obstacle is that intestinal blood supply supplies hypoxgia or and has proteinacious malnutrition to cause intestinal cell metabolism substrate deficiency, synthesize mucoprotein insufficient raw material etc.
Content of the present invention is the combination formula of Chinese crude drug Ganoderma and injection Vitamin B_6, A and beta-carotene.
Ganoderma has the effect strengthening blood of human body supply and oxygen supply.
The oxygen reserves of human body is relative to very pettiness nutrient deposit, and may cause damage because oxygen supply is not enough to human body when human body has excess oxygen consumption demand, old friend's body increases oxygen supply when morbid state particularly important.
Injection Vitamin B_6, A and beta-carotene have the effect preventing oxygen-derived free radicals activity, scavenging activated oxygen, protection human body cell.
Apply formula of the present invention, intestinal tissue blood supply and oxygen supply can be strengthened, for the generation of goblet cell, reparation, renewal and normal work provide sufficient nutrition and oxygen, furnish ample material and oxygen for goblet cell secretion is mucoprotein, thus build normal intestinal tract surface slime layer barrier, stop Intestinal Antigens close, contact, adhere to and enter into intestinal tissue, stop the generation of abnormal immune response, and then reach the termination of inflammation and the reparation of intestinal tissue, the mechanism of action of Here it is prescription therapeutic inflammatory bowel of the present invention.
Pathologic data shows, Leukocyte Killing, degraded pathogen, antigen, fragment of tissue need to consume than the oxygen of many 2 ~ 20 times time normal, so the oxygen supply that inflammatory bowel patient strengthens inflammation part is extremely important to the efficiency of inflammation and the termination of inflammation.
Human body can produce a large amount of oxygen-derived free radicals under inflammatory conditions, and oxygen-derived free radicals can cause damage to body, affects the termination of inflammation and the reparation of tissue.
The present invention applies the oxygen supply that Ganoderma can strengthen intestinal tissue, thus accelerates the removing of antigen in intestinal tissue, accelerates the generation of intestinal tissue cell, reparation, renewal process, also can produce more oxygen-derived free radicals simultaneously.Injection Vitamin B_6, A and beta-carotene have the effect preventing oxygen-derived free radicals activity, scavenging activated oxygen, protection human body cell, thus inflammatory bowel patient while taking Ganoderma, supplement the reparation of these vitamin to the termination of enteritis and tissue especially necessary.
Ganoderma of the present invention is the Ganoderma sporophore that the Pharmacopoeia of the People's Republic of China specifies, does not especially still discharge the ganoderma lucidum sporocarp of spore as well to be about to maturation.Consumption in detailed description of the invention measures with the Ganoderma sporophore of drying.
Formula of the present invention can be made into masticatory, containing agent and oral agents, with masticatory, best containing agent effect.
According to mucosal immune system (mucosalimmunesystem), the mucosa traversal system (mucosalmigrationsystem of Medical Immunology, MMS) and " immunity is patrolled and examined " theoretical, the imbalance of intestinal tract surface slime layer barrier can also cause the diseases such as such as periphery arthritis, erythema nodosum, Pyoderma gangrenosum, episcleritis, recurrent oral ulceration; The imbalance of intestinal tract surface slime layer barrier also may cause autoimmune disease, rheumatism and anaphylactic disease.The important research field that the relation of probing into intestinal tract surface slime layer barrier and disease will be 21 century preclinical medicine.Build normal intestinal tract surface slime layer barrier, the intestinal tissue of repairing damage is important content of the present invention, is the primary efficacy of formula of the present invention.
A large amount of facts have proved, applies the long-term diarrhea of prescription therapeutic irritable bowel syndrome of the present invention, infectious diarrhea and unknown cause, asthma, allergic rhinitis have reliable effect.
According to the theory of the combination of Chinese and Western medicine, the disease of human body comes from deficiency of vital energy blood deficiency mostly, and formula of the present invention can strengthen blood supply and the oxygen supply of human body integral, so have good therapeutical effect to the people of deficiency of vital energy blood deficiency.
Reinforce according to healthy and beautiful longevity and says, disease, the aging of human body are mostly relevant with body hypoxic-ischemic, solution body hypoxic-ischemic problem, and most of disease can prevention and therapy, and human longevity can significantly extend.
Detailed description of the invention
One, Ganoderma 0.5 gram, vitamin C 50 milligrams, vitamin E 4 milligrams, vitamin A 0.1 milligram, beta-carotene 0.6 milligram are made into masticatory, every day 2 to 4 times.
Two, Ganoderma 0.25 gram, Catergen 5 milligrams, vitamin E2 milligram, vitamin A 0.05 milligram, beta-carotene 0.3 milligram are made into masticatory, every day 2 to 4 times.
Three, Ganoderma 0.5 gram, vitamin C 50 milligrams, vitamin E 4 milligrams, vitamin A 0.1 milligram, beta-carotene 0.6 milligram are made into containing agent, every day 2 to 4 times.
Four, Ganoderma 0.25 gram, Catergen 5 milligrams, vitamin E2 milligram, vitamin A 0.05 milligram, beta-carotene 0.3 milligram are made into containing agent, every day 2 to 4 times.
Five, Ganoderma 5 grams, vitamin C 50 milligrams, vitamin E 4 milligrams, vitamin A 0.1 milligram, beta-carotene 0.6 milligram are made into oral agents, every day 2 to 4 times.
Six, Ganoderma 2.5 grams, Catergen 5 milligrams, vitamin E2 milligram, vitamin A 0.05 milligram, beta-carotene 0.3 milligram are made into oral agents, every day 2 to 4 times.
Claims (1)
1. treat a prescription for inflammatory bowel, its prescription is characterized as: Ganoderma 5 ~ 50 parts, vitamin C 0.5 part, vitamin E 0.04 part, vitamin A 0.001 part, beta-carotene 0.006 part.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510937003.2A CN105362303A (en) | 2015-12-16 | 2015-12-16 | Composition for treating inflammatory bowel disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510937003.2A CN105362303A (en) | 2015-12-16 | 2015-12-16 | Composition for treating inflammatory bowel disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105362303A true CN105362303A (en) | 2016-03-02 |
Family
ID=55365257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510937003.2A Pending CN105362303A (en) | 2015-12-16 | 2015-12-16 | Composition for treating inflammatory bowel disease |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105362303A (en) |
-
2015
- 2015-12-16 CN CN201510937003.2A patent/CN105362303A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105412157A (en) | Composition for treating inflammatory bowel disease | |
CN105362306A (en) | Composition for treating inflammatory bowel disease | |
CN105412237A (en) | Composition for treating inflammatory bowel disease | |
CN105362303A (en) | Composition for treating inflammatory bowel disease | |
CN105434524A (en) | Composition for treating inflammatory bowel disease | |
CN105343172A (en) | Prescription for treating inflammatory bowel disease | |
CN105343136A (en) | Prescription for treating inflammatory bowel disease | |
CN105412164A (en) | Composition for treating inflammatory bowel disease | |
CN105362305A (en) | Composition for treating inflammatory bowel disease | |
CN105412166A (en) | Composition for treating inflammatory bowel disease | |
CN105412163A (en) | Composition for treating inflammatory bowel disease | |
CN105412239A (en) | Composition for treating inflammatory bowel disease | |
CN105362304A (en) | Composition for treating inflammatory bowel disease | |
CN105456319A (en) | Formula for treating inflammatory bowel disease | |
CN105412165A (en) | Composition for treating inflammatory bowel disease | |
CN105412160A (en) | Composition for treating inflammatory bowel disease | |
CN105412233A (en) | Composition for treating inflammatory bowel disease | |
CN105412158A (en) | Composition for treating inflammatory bowel disease | |
CN105412234A (en) | Composition for treating inflammatory bowel disease | |
CN105477062A (en) | Composition for treating inflammatory bowel diseases | |
CN105477023A (en) | Prescription for treating inflammatory bowel disease | |
CN105412190A (en) | Composition for treating inflammatory bowel disease | |
CN105412236A (en) | Composition for treating inflammatory bowel disease | |
CN105477060A (en) | Prescription for treating inflammatory bowel disease | |
CN105456318A (en) | Composition for treating inflammatory bowel diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160302 |
|
WD01 | Invention patent application deemed withdrawn after publication |